An Evaluation and Improvement Program for Inpatient Anticoagulant Control

Summary

To improve the management and therapeutic control of inpatients on anticoagulant drugs, combined prescription and monitoring charts have been developed for both heparin and warfarin which incorporate clinical guidelines. These have been introduced throughout a 700-bedded acute teaching hospital via a structured program of change management.

We have demonstrated improvements in the quality of anticoagulant control (assessed with a custom-written computer program), adherence to clinical guidelines and quality of monitoring and prescribing of anticoagulants in inpatients.

The percentage time spent under-anticoagulated with heparin (activated partial thromboplastin time ratio <1.5) fell from 32.7% to 18.5% (p<0.0001), whereas there was no change in percentage time over-anticoagulated (5.1% vs. 5.8%; p = ns). The percentage time spent under-anticoagulated with warfarin was unaltered (26.3% vs. 29.8%; p = ns) but the percentage time spent over-anticoagulated (International Normalised Ratio >4.5) was halved from 5.4% to 2.7% (p<0.001).

We conclude that the introduction of the charts led to significant improvements in anticoagulant control.

• References

• 1 Phillips WS, Makris M, Preston FE. Audit of the frequency and clinical response to excessive oral anticoagulation. Br J Haematol 1993; 84 (Suppl. 01) 57S
• 2 BCSH Haemostasis and Thrombosis Task Force. The British Society for Haematology Guidelines on the use and monitoring of heparin 1992: Second revision. J Clin Pathol. 1993; 46: 97-103
• 3 British Society for Haematology. British Committee for Standards in Haematology. Haemostasis and Thrombosis Task Force. Guidelines on oral anticoagulation: second edition. J Clin Pathol 1990; 43: 177-183
• 4 Fennerty A, Campbell IA, Routledge PA. Anticoagulants in venous thromboembolism. BMJ 1988; 297: 1285-1288
• 5 Anonymous. How to anticoagulate. Drug Ther Bull 1992; 20: 77-80
• 6 Grimshaw J, Freemantle N, Wallace S, Russell I, Hurwitz B, Watt I, Long A, Sheldon T. Developing and implementing clinical practice guidelines. Qual Health Care 1995; 04: 55-64
• 7 Emslie C, Grimshaw J, Templeton A. Do clinical guidelines improve general practice management and referral of infertile couples?. BMJ 1993; 306: 1728-1731
• 8 Stroke prevention in atrial fibrillation investigators. Warfarin versus aspirin for the prevention of thromboembolism in atrial fibrillation: Stroke prevention atrial fibrillation II study. Lancet 1994; 343: 687-691
• 9 Poller L, Wright D, Rowlands M. Prospective comparative study of computer programs used for management of warfarin. J Clin Pathol 1993; 46: 299-303
• 10 EAFT (European Atrial Fibrillation Trial) Study Group. Secondary prevention in non-rheumatic atrial fibrillation after transient ischaemic attack or minor stroke. Lancet 1993; 342: 1255-1262
• 11 Rosendaal FR, Cannagieter SC, van der Meer FJM, Briët E. A method to determine the optimal intensity of oral anticoagulant therapy. Thromb Haemost 1993; 69: 236-239
• 12 Phillips WS, Collin R, Preston FE, Makris M. Application of the method of Rosendaal et al. to the assessment of anticoagulant control in a number of clinical settings. B J Haematol (Suppl. 01) 1995; 89: 28
• 13 Azar AJ, Deckers JW, Rosendaal FR, van Bergen PFMM, van der Meer FJM, Jonker JJC, Briët E. Assessment of therapeutic quality control in a long term anticoagulant trial in post-myocardial patients. Thromb Haemost 1994; 72: 347-351
• 14 Hull RD, Raskob GE, Hirsh J, Jay RM, Leclerc JR, Geerts WH, Rosen-bloom D, Sackett DL, Anderson C, Harrison L, Gent M. Continuous intravenous heparin compared with intermittent subcutaneous heparin in the initial treatment of proximal-vein thrombosis. N Engl J Med 1986; 315: 1109-1114
• 15 Hirsh J, Siragusa S, Cosmi B, Ginsberg JS. Low molecular weight heparins (LMWH) in the treatment of patients with acute venous thromboembolism. Thromb Haemost 1995; 74: 360-363
• 16 Hull RD, Raskob GE, Rosenbloom D, Lemaire J, Pineo GF, Baylis B, Ginsberg JS, Panju AA, Brill-Edwards PE, Brant R. Optimal therapeutic level of heparin therapy in patients with venous thrombosis. Arch Intern Med 1992; 152: 1589-1595
• 17 Basu D, Gallus A, Hirsh J, Cade J. A prospective study of the value of monitoring heparin treatment with the activated partial thromboplastin time. N Engl J Med 1972; 287: 324-327